Business
Caris Life Sciences to Share Six Collaborative Studies at ESMO 2025
IRVING, Texas, Oct. 14, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"\n IRVING, Texas, Oct. 14, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, will unveil six studies at the European Society for Medical Oncology (ESMO) Congress 2025, in Berlin, Germany from October 17-21, 2025. These presentations highlight the transformative power of multiomics, a scientific approach that integrates data from multiple biological layers to achieve a comprehensive understanding of biological systems and disease. The research spans nine tumor types, and results showcase how integrated profiling, subtyping, and biomarker discovery are driving more informed treatment decisions and improving patient outcomes.\n \n \n \n \n \n \n \n The six studies were conducted in collaboration with more than 25 leading cancer centers across the U.S., Europe, and Japan, including members of the Caris Precision Oncology Alliance®. The research will be featured across multiple formats, including one oral \"Proffered Paper,\" one mini-oral and four poster presentations. The studies highlight Caris' continued leadership in applying next-generation sequencing (WES and WTS), immunohistochemistry (IHC) and real-world clinico-genomic data to uncover actionable insights. Tumor types represented include colorectal, gastric, breast, pancreatic, head & neck, prostate, urothelial, renal, and biliary tract cancers.\n \"By integrating real-world data, advanced sequencing and biomarker discovery, we're refining cancer subtyping and treatment decisions to improve patient outcomes across numerous cancer types,' said Milan Radovich, PhD, Senior Vice President and Chief Scientific Officer at Caris. \"ESMO provides an international stage to share these insights and accelerate the future of personalized cancer care.\"\n \n \n Oral 'Proffered Paper' includes:\n \n \n \n \n The Mechanism of Mismatch Repair Deficiency (MMRd) Informs Survival Outcomes Derived from Immune Checkpoint Blockade (ICB) Across MMRd Solid Tumors (Presentation Number: 1110)Saturday, Oct 18, 2025\n \n \n \n Mini-oral includes:\n \n \n \n \n Comprehensive Multi-Omics Analysis of Early-Onset Cancer: Insights from the MONSTAR-SCREEN-2 Experience (Presentation Number: 115MO)Saturday, Oct 18, 2025 \n \n \n \n Posters include:\n \n \n \n \n Impact of Androgen Deprivation Therapy (ADT) on ...